New drug combo shows promise for chinese men with advanced prostate cancer
NCT ID NCT04076059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it took for PSA levels to rise, a sign of cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enzalutamide (Xtandi)
What this could lead to
If successful, this combination could become a new standard treatment for Chinese men with metastatic hormone-sensitive prostate cancer, delaying disease progression.
What could go wrong
This is a phase 3 trial, but results may not apply to all populations. Side effects of enzalutamide include fatigue, hot flashes, and high blood pressure. The study is complete but not yet published.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site CN86001
Guangzhou, China
-
Site CN86002
Shanghai, China
-
Site CN86003
Shanghai, China
-
Site CN86004
Nanchang, China
-
Site CN86005
Ürümqi, China
-
Site CN86009
Changsha, China
-
Site CN86010
Shanghai, China
-
Site CN86011
Shenzhen, China
-
Site CN86012
Tianjin, China
-
Site CN86013
Shanghai, China
-
Site CN86014
Shanghai, China
-
Site CN86016
Changsha, China
-
Site CN86017
Zhengzhou, China
-
Site CN86019
Wuhan, China
-
Site CN86020
Shenyang, China
-
Site CN86021
Wuxi, China
-
Site CN86022
Beijing, China
-
Site CN86023
Changsha, China
-
Site CN86024
Changchun, China
-
Site CN86025
Fuzhou, China
-
Site CN86026
Wuhan, China
-
Site CN86027
Shanghai, China
-
Site CN86028
Hangzhou, China
-
Site CN86029
Zhengzhou, China
-
Site CN86032
Suzhou, China
-
Site CN86035
Beijing, China
-
Site CN86036
Hangzhou, China
-
Site CN86038
Xi'an, China